Research programme: PARP-1 inhibitors - IMPACT Therapeutics

Drug Profile

Research programme: PARP-1 inhibitors - IMPACT Therapeutics

Alternative Names: IMP 4297; IMP04297

Latest Information Update: 13 Jun 2016

Price : $50

At a glance

  • Originator IMPACT Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 06 May 2016 IMPACT Therapeutics plans a phase I trial in Solid tumours (Late-stage disease) in Australia (ACTRN12616000689471p)
  • 25 Feb 2016 IMPACT Therapeutics has patent protection for its PARP-1 inhibitors in China (Company website-Feb 2016)
  • 25 Feb 2016 Research programme: PARP-1 inhibitors - IMPACT Therapeutics is available for licensing as of 25 Feb 2016. http://www.impacttherapeutics.com/english/about/about.asp
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top